Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brachytherapy Gains Momentum With 12-Year Survival Data Released At AUA

This article was originally published in The Gray Sheet

Executive Summary

Favorable long-term efficacy data continue to fuel rapid growth in prostate cancer brachytherapy, which physicians predict will be the treatment of choice in 25% of cases in 2000.

You may also be interested in...

Bard Views GI, AAA Devices And Brachytherapy Seeds As Key Growth Drivers

Bard is hopeful that the Health Care Financing Administration will deem the firm's endoscopic suturing system for gastroesophageal reflux disease eligible for supplementary reimbursement under the agency's outpatient prospective payment system.

Uromed, Implant Sciences Join Prostate Cancer Brachytherapy Free-For-All

Uromed and Implant Sciences are the most recent entries into the rapidly growing market for prostate-brachytherapy seeds, estimated at $150 mil. in 1999.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts